• Yunhong Huang
  • Aneta Skwarek-Maruszewska
  • Katrien Horré
  • Elke Vandewyer
  • Leen Wolfs
  • An Snellinx
  • Takashi Saito
  • Enrico Radaelli
  • Nikky Corthout
  • Julien Colombelli
  • Adrian C Lo
  • Leen Van Aerschot
  • Zsuzsanna Callaerts-Vegh
  • Daniah Trabzuni
  • Koen Bossers
  • Joost Verhaagen
  • Mina Ryten
  • Sebastian Munck
  • Rudi D'Hooge
  • John Hardy
  • Takaomi C Saido
  • Bart De Strooper
  • Amantha Thathiah

The orphan G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptor (GPCR) GPR3 regulates activity of the γ-secretase complex in the absence of an effect on Notch proteolysis, providing a potential therapeutic target for Alzheimer's disease (AD). However, given the vast resources required to develop and evaluate any new therapy for AD and the multiple failures involved in translational research, demonstration of the pathophysiological relevance of research findings in multiple disease-relevant models is necessary before initiating costly drug development programs. We evaluated the physiological consequences of loss of Gpr3 in four AD transgenic mouse models, including two that contain the humanized murine Aβ sequence and express similar amyloid precursor protein (APP) levels as wild-type mice, thereby reducing potential artificial phenotypes. Our findings reveal that genetic deletion of Gpr3 reduced amyloid pathology in all of the AD mouse models and alleviated cognitive deficits in APP/PS1 mice. Additional three-dimensional visualization and analysis of the amyloid plaque burden provided accurate information on the amyloid load, distribution, and volume in the structurally intact adult mouse brain. Analysis of 10 different regions in healthy human postmortem brain tissue indicated that GPR3 expression was stable during aging. However, two cohorts of human AD postmortem brain tissue samples showed a correlation between elevated GPR3 and AD progression. Collectively, these studies provide evidence that GPR3 mediates the amyloidogenic proteolysis of APP in four AD transgenic mouse models as well as the physiological processing of APP in wild-type mice, suggesting that GPR3 may be a potential therapeutic target for AD drug development.

Original languageEnglish
Pages (from-to)309ra164
JournalScience Translational Medicine
Volume7
Issue number309
DOI
StatePublished - 14 Oct 2015

ID: 1544601